Valsartan (BioDeep_00000397478)

   

natural product


代谢物信息卡片


Valsartan (Diovan)

化学式: C24H29N5O3 (435.2270284)
中文名称: 缬沙坦
谱图信息: 最多检出来源 Homo sapiens(natural_products) 83.33%

分子结构信息

SMILES: C1(=CC=C(C=C1)C2=CC=CC=C2C3N=NNN=3)CN([C@@](C(C)C)(C(=O)O)[H])C(=O)CCCC
InChI: InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

描述信息

C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
D057911 - Angiotensin Receptor Antagonists > D047228 - Angiotensin II Type 1 Receptor Blockers
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 1075
CONFIDENCE standard compound; INTERNAL_ID 1112
CONFIDENCE standard compound; INTERNAL_ID 8608
CONFIDENCE standard compound; EAWAG_UCHEM_ID 2583
INTERNAL_ID 1112; CONFIDENCE standard compound
Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research[1].

同义名列表

3 个代谢物同义名

Valsartan; Valsartan (Diovan); CGP 48933



数据库引用编号

78 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Fang Wang, Chengde Li, Xuezheng Zhang. Sacubitril/valsartan improves the prognosis of acute myocardial infarction: a meta-analysis. Coronary artery disease. 2024 May; 35(3):231-238. doi: 10.1097/mca.0000000000001332. [PMID: 38299259]
  • Manzhi Li, Ao Zhong, Yifan Tang, Jinnuo Yu, Mengmeng Wu, Karthick Kumaran Munisamy Selvam, Dong Sun. Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study. Lipids in health and disease. 2024 Feb; 23(1):63. doi: 10.1186/s12944-024-02051-x. [PMID: 38419057]
  • Hua Qu, A-Ling Shen, Kuo Yang, Ming-Yan Huang, Hong-Zheng Li, Wen-Wen Yang, Shu-Yue Fan, Ling Tan, Jie Wang, Yu-Xuan Peng, Jian-Feng Chu, Jun Peng, Chang-Geng Fu, Lin-Zi Long, Ke-Ji Chen. Efficacy and safety of Qingda granule versus valsartan capsule in Chinese grade 1 hypertensive patients with low-moderate risk: A randomized, double-blind, double dummy, non-inferiority, multi-center trial. Pharmacological research. 2024 Feb; 200(?):107052. doi: 10.1016/j.phrs.2023.107052. [PMID: 38181857]
  • Valentin Göldner, Jessica Ulke, Benedict Kirchner, Dominik Skalka, Marie Schmalz, Steffen Heuckeroth, Uwe Karst. Electrochemistry-mass spectrometry bridging the gap between suspect and target screening of valsartan transformation products in wastewater treatment plant effluent. Water research. 2023 Oct; 244(?):120525. doi: 10.1016/j.watres.2023.120525. [PMID: 37669607]
  • - Magdy I Mohamed, - Hanaa A Mahmoud, - Amir I Mohamed, - Nesrin M Nabil, - Mohamed A Kasssem, - Yousef A Elsherif. Formulation, in-vitro evaluation and optimization of valsartan nano-lipid complex by Box-Behnken design. Pakistan journal of pharmaceutical sciences. 2023 Jul; 36(4):1249-1260. doi: ". [PMID: 37599502]
  • Z Dogan, D D Ergun, S Durmus, H Sahin, G E Senturk, R Gelisgen, A Senyigit, H Uzun. Empagliflozin and sacubitril/valsartan reverse methotrexate cardiotoxicity by repressing oxidative stress and hypoxia in heart embryonic H9c2 cardiomyocytes - the role of morphology of mitochondria observed on electron microscopy. European review for medical and pharmacological sciences. 2023 05; 27(9):3979-3992. doi: 10.26355/eurrev_202305_32304. [PMID: 37203822]
  • Meizhu Wu, Siyu Zhang, Wenqiang Zhang, Yuting Zhou, Zhi Guo, Yi Fang, Yanyan Yang, Zhiqing Shen, Dawei Lian, Aling Shen, Jun Peng. Qingda granule ameliorates vascular remodeling and phenotypic transformation of adventitial fibroblasts via suppressing the TGF-β1/Smad2/3 pathway. Journal of ethnopharmacology. 2023 Apr; 313(?):116535. doi: 10.1016/j.jep.2023.116535. [PMID: 37100260]
  • Jia Su, Yingchu Hu, Ji Cheng, Zhenwei Li, Jiyi Li, Nan Zheng, Zhaoxia Zhang, Jin Yang, Xiaojin Li, Qinglin Yu, Weiping Du, Xiaomin Chen. Comprehensive analysis of the RNA transcriptome expression profiles and construction of the ceRNA network in heart failure patients with sacubitril/valsartan therapeutic heterogeneity after acute myocardial infarction. European journal of pharmacology. 2023 Apr; 944(?):175547. doi: 10.1016/j.ejphar.2023.175547. [PMID: 36708978]
  • Cong Han, Zhen Shen, Tao Cui, Shan-Shan Ai, Ran-Ran Gao, Yao Liu, Gui-Yuan Sui, Hong-Zhen Hu, Wei Li. Yi-Shen-Hua-Shi granule ameliorates diabetic kidney disease by the "gut-kidney axis". Journal of ethnopharmacology. 2023 Feb; 307(?):116257. doi: 10.1016/j.jep.2023.116257. [PMID: 36787845]
  • Rui Li, Chuanzhou Liang, Sif B Svendsen, Vaidotas Kisielius, Kai Bester. Sartan blood pressure regulators in classical and biofilm wastewater treatment - Concentrations and metabolism. Water research. 2023 Feb; 229(?):119352. doi: 10.1016/j.watres.2022.119352. [PMID: 36450176]
  • Weiquan Zeng, Xiuli Zhang, Yao Lu, Ying Wen, Qiurong Xie, Xuan Yang, Shuyu He, Zhi Guo, Jiapeng Li, Aling Shen, Jun Peng. Neferine ameliorates hypertensive vascular remodeling modulating multiple signaling pathways in spontaneously hypertensive rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Feb; 158(?):114203. doi: 10.1016/j.biopha.2022.114203. [PMID: 36916429]
  • Lin-Zi Long, Jian-Feng Chu, Hua Qu, Qiao-Ning Yang, Yan Lu, Chang-Geng Fu, Jun Peng, Ke-Ji Chen. Effects of Qingda granule on patients with grade 1 hypertension at low-medium risk: study protocol for a randomized, controlled, double-blind clinical trial. Trials. 2023 Jan; 24(1):1. doi: 10.1186/s13063-022-07006-0. [PMID: 36588157]
  • Yue Jin, Lin Zeng, Mengjun Xiao, Yanan Feng, Zhihui Gao, Jianhe Wei. Exploration of the B3 transcription factor superfamily in Aquilaria sinensis reveal their involvement in seed recalcitrance and agarwood formation. PloS one. 2023; 18(11):e0294358. doi: 10.1371/journal.pone.0294358. [PMID: 37972007]
  • Yuanrui Huang, Xu Wu, Xingyu Li, Zhengzhong Liu, Yunyi Li. Effect on the Quality of Life of Patients with Heart Failure and Reduced/Preserved Ejection Fraction Using Sacubitril/Valsartan. Arquivos brasileiros de cardiologia. 2023; 120(8):e20220611. doi: 10.36660/abc.20220611. [PMID: 37971045]
  • Kwang Je Lee, Jae-Kean Ryu, Yun-Hyeong Cho, Won Yong Shin, Jeong Su Kim, Young Won Yoon, Ji Yong Jang, Won Ho Kim, Jong Wook Beom, Seok-Min Kang. Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study. Drug design, development and therapy. 2023; 17(?):1047-1062. doi: 10.2147/dddt.s391288. [PMID: 37051292]
  • Eda Gülmezoğlu, Gülbeyaz Yıldız Türkyılmaz, H Yeşim Karasulu. Preparation and evaluation of a lipid-based drug delivery system to ımprove valsartan oral bioavailability: pharmacokinetic and pharmacodynamic analysis. Drug development and industrial pharmacy. 2022 Dec; 48(12):727-736. doi: 10.1080/03639045.2022.2164588. [PMID: 36594276]
  • Md Sayeed Akhtar, Md Quamrul Hassan, Obaid Afzal, Abdulmalik S A Altamimi, Mohd Zaheen Hassan, Arun Kumar, Asif Ansari Shaik Mohammad, Fauzia Tabassum. Comparative efficacy of levosimendan, ramipril, and sacubitril/valsartan in isoproterenol induced experimental heart failure: a hemodynamic and molecular approach. Current molecular pharmacology. 2022 Sep; ?(?):. doi: 10.2174/1874467215666220919104526. [PMID: 36121084]
  • Dina Salem Abdelaziz Elshenawy, Nehal Mohammed Ramadan, Vivian Boshra Abdo, Rehab Hamdy Ashour. Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Sep; 153(?):113382. doi: 10.1016/j.biopha.2022.113382. [PMID: 36076522]
  • Yihai Liu, Chongxia Zhong, Jiayi Si, Shan Chen, Lina Kang, Biao Xu. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats. Journal of hypertension. 2022 09; 40(9):1822-1830. doi: 10.1097/hjh.0000000000003230. [PMID: 35943105]
  • Ruoyu Jia, Xuejie Zhang, Yizhou Xu, Zhifang Zheng, Luhua Jiang, Xin Zhang, Chen Sun, Xin Wu, Shulin Li, Ashok Raj, Dong Sun. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study. European journal of pharmacology. 2022 Aug; 928(?):175053. doi: 10.1016/j.ejphar.2022.175053. [PMID: 35709921]
  • Ali Akbar Asghari, Maryam Mahmoudabady, Sadegh Shabab, Saeed Niazmand. Anti-inflammatory, anti-oxidant and anti-apoptotic effects of olive leaf extract in cardiac tissue of diabetic rats. The Journal of pharmacy and pharmacology. 2022 Jul; 74(7):961-972. doi: 10.1093/jpp/rgac019. [PMID: 35551403]
  • L Q Peng, X X Wu, G Chen, H Z Cai, Y P Tang, Q Y Chen, X Y Chen. Effects of Wenyang Zhenshuai Granules on the Expression of Key Mitochondrial Autophagy Proteins in the Doxorubicin-Induced Model of H9c2 Cardiomyocyte Injury. Bulletin of experimental biology and medicine. 2022 Jul; 173(3):335-340. doi: 10.1007/s10517-022-05545-9. [PMID: 35854020]
  • Rama Sivasubramanian, Gangadhar Sunkara, Rajesh Karan, Wei Zhou, Yiming Zhang, Ramachandra Sangana. The Bioequivalence Between Valsartan Oral Solution and Suspension Formulations Developed for Pediatric Use. Clinical pharmacology in drug development. 2022 Jul; 11(7):843-848. doi: 10.1002/cpdd.1069. [PMID: 35050548]
  • Hasan Ali Barman, Selim Tanyolaç, Omer Dogan, Erdem Bal, Adem Atıcı, Serhan Özyıldırım, Zerrin Yiğit. Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction. Clinical drug investigation. 2022 Jun; 42(6):533-540. doi: 10.1007/s40261-022-01161-7. [PMID: 35635714]
  • Lei Yang, Nan Ye, Weijing Bian, Hong Cheng. Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis. International urology and nephrology. 2022 Jun; 54(6):1435-1444. doi: 10.1007/s11255-021-03025-z. [PMID: 34669107]
  • Tatsuki Mochizuki, Maciej J Zamek-Gliszczynski, Kenta Yoshida, Jialin Mao, Kunal Taskar, Hideki Hirabayashi, Xiaoyan Chu, Yurong Lai, Tadayuki Takashima, Kevin Rockich, Yoshiyuki Yamaura, Kaku Fujiwara, Tadahaya Mizuno, Kazuya Maeda, Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara. Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions. Clinical pharmacology and therapeutics. 2022 06; 111(6):1315-1323. doi: 10.1002/cpt.2584. [PMID: 35292967]
  • Selly D Msungu, Arnold A Mushongi, Pavithravani B Venkataramana, Ernest R Mbega. Status of carotenoids in elite and landrace maize genotypes: Implications for provitamin A biofortification in Tanzania. Food research international (Ottawa, Ont.). 2022 06; 156(?):111303. doi: 10.1016/j.foodres.2022.111303. [PMID: 35651063]
  • Paolo Tolomeo, Ottavio Zucchetti, Emanuele D'Aniello, Noemi Punzo, Federico Marchini, Luca Di Ienno, Elisabetta Tonet, Rita Pavasini, Claudio Rapezzi, Gianluca Campo, Matteo Serenelli. Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index. ESC heart failure. 2022 06; 9(3):2037-2043. doi: 10.1002/ehf2.13891. [PMID: 35318819]
  • Thibault Michel, Hélène Nougué, Jérôme Cartailler, Guillaume Lefèvre, Malha Sadoune, François Picard, Alain Cohen-Solal, Damien Logeart, Jean-Marie Launay, Nicolas Vodovar. proANP Metabolism Provides New Insights Into Sacubitril/Valsartan Mode of Action. Circulation research. 2022 05; 130(11):e44-e57. doi: 10.1161/circresaha.122.320882. [PMID: 35485239]
  • Simon Thonsgaard, Timothy C R Prickett, Lasse H Hansen, Nicolai J Wewer Albrechtsen, Ulrik Ø Andersen, Dijana Terzic, Peter Plomgaard, Finn Gustafsson, Jens P Goetze, Peter D Mark. Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men. Clinical chemistry. 2022 05; 68(5):713-720. doi: 10.1093/clinchem/hvac005. [PMID: 35175317]
  • Giovanni Battista Bolla, Antonella Fedele, Andrea Faggiano, Carla Sala, Gloria Santangelo, Stefano Carugo. Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction. BMC cardiovascular disorders. 2022 05; 22(1):217. doi: 10.1186/s12872-022-02647-0. [PMID: 35562650]
  • Joo Young Na, Eunsol Yang, Jae-Hoon Kim, In Sun Kwon, Eun-Heui Jin, Kyung-Sang Yu, Jinsook Kim, SeungHwan Lee, Jang Hee Hong. Comparative Pharmacokinetics Between a Fixed-Dose Combination of Pitavastatin/Valsartan 4/160 mg and the Corresponding Individual Components Through a Partial Replicated Crossover Design in Healthy Male Subjects. Clinical pharmacology in drug development. 2022 05; 11(5):615-622. doi: 10.1002/cpdd.1054. [PMID: 34997835]
  • Alexander Peikert, Muthiah Vaduganathan, Finnian Mc Causland, Brian L Claggett, Safia Chatur, Milton Packer, Marc A Pfeffer, Faiez Zannad, Martin P Lefkowitz, Burkert Pieske, Hans-Dirk Düngen, John J V McMurray, Scott D Solomon. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. European journal of heart failure. 2022 May; 24(5):794-803. doi: 10.1002/ejhf.2450. [PMID: 35119183]
  • Giuseppe M C Rosano, Simone Celant, Pier Paolo Olimpieri, Antonietta Colatrella, Graziano Onder, Andrea Di Lenarda, Giuseppe Ambrosio, Gianpaolo Reboldi, Gian Franco Gensini, Furio Colivicchi, Pierluigi Russo. Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy. European journal of heart failure. 2022 May; 24(5):855-860. doi: 10.1002/ejhf.2490. [PMID: 35303393]
  • Geert H D Voordes, Hiddo J L Heerspink, Jozine M Ter Maaten. The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function. European journal of heart failure. 2022 May; 24(5):804-806. doi: 10.1002/ejhf.2501. [PMID: 35415946]
  • Yan Zhou, Mengmeng Wei, Mingkang Zhang, Jianping Zhang, Fabing Tang, Xin'an Wu. Adefovir accumulation in the renal interstitium triggers mast cell degranulation and promotes renal interstitial fibrosis. Toxicology letters. 2022 Apr; 359(?):10-21. doi: 10.1016/j.toxlet.2022.01.018. [PMID: 35114312]
  • Shuhong Li, Lixin Dong, Keqin Tang, Zhenwei Lan, Rong Liu, Yuanjian Wang, Ruixun Wang, Huaqing Lin. Simultaneous and trace level quantification of two potential genotoxic impurities in valsartan drug substance using UPLC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2022 Apr; 212(?):114630. doi: 10.1016/j.jpba.2022.114630. [PMID: 35158183]
  • Kristian Hellenkamp, Kathleen Nolte, Stephan von Haehling. Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. Expert opinion on pharmacotherapy. 2022 Apr; 23(6):673-680. doi: 10.1080/14656566.2022.2047647. [PMID: 35260016]
  • Pei-Hsun Sung, Han-Tan Chai, Chih-Chao Yang, John Y Chiang, Chih-Hung Chen, Yi-Ling Chen, Hon-Kan Yip. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Apr; 148(?):112745. doi: 10.1016/j.biopha.2022.112745. [PMID: 35202913]
  • Yong-Rong Li, Hai-Bin Xie, Hong Li, Jie Sun. [Protective effects of dexamethasone combined with valsartan on chronic obstructive pulmonary disease in mice and its mechanism]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology. 2022 Mar; 38(2):149-153. doi: 10.12047/j.cjap.6202.2022.019. [PMID: 36031573]
  • Yu Wang, Zhen Hua, Wenjing Chen, Yushuo Zhu, Yunlun Li. Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Trials. 2022 Feb; 23(1):171. doi: 10.1186/s13063-022-06089-z. [PMID: 35193665]
  • Shoichiro Daimon, Miyuki Yasuda, Kazumasa Maeda. Effect of sacubitril-valsartan on cardiac function in hemodialysis patients. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2022 02; 26(1):244-245. doi: 10.1111/1744-9987.13715. [PMID: 34327839]
  • Jiaru Lin, Li Wang, Bo Chen, Santao Ou, Jianhua Qin, Junming Fan. Shenweifang-containing serum inhibits transforming growth factor-β1 induced myofibroblast differentiation in normal rat kidney interstitial fibroblast cell. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. 2022 02; 42(1):39-48. doi: NULL. [PMID: 35294121]
  • Chih-Chao Yang, Pei-Hsun Sung, Kuan-Hung Chen, Han-Tan Chai, John Y Chiang, Sheung-Fat Ko, Fan-Yen Lee, Hon-Kan Yip. Valsartan- and melatonin-supported adipose-derived mesenchymal stem cells preserve renal function in chronic kidney disease rat through upregulation of prion protein participated in promoting PI3K-Akt-mTOR signaling and cell proliferation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Feb; 146(?):112551. doi: 10.1016/j.biopha.2021.112551. [PMID: 34923336]
  • Michael Böhm, Birgit Assmus, Stefan D Anker, Folkert W Asselbergs, Johannes Brachmann, Marie-Elena Brett, Jasper J Brugts, Georg Ertl, AiJia Wang, Lutz Hilker, Friedrich Koehler, Stephan Rosenkranz, David M Leistner, Amr Abdin, Jan Wintrich, Qian Zhou, Philip B Adamson, Christiane E Angermann. Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. ESC heart failure. 2022 02; 9(1):155-163. doi: 10.1002/ehf2.13665. [PMID: 34738340]
  • Jing Yan, Defeng Li, Qin Liu, Yuanlan Xie. Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1. Computational and mathematical methods in medicine. 2022; 2022(?):7982023. doi: 10.1155/2022/7982023. [PMID: 35572824]
  • Zhonglin Feng, Xipei Wang, Li Zhang, Rizvangul Apaer, Lixia Xu, Jianchao Ma, Xinyi Li, Huimin Che, Bin Tang, Yuwang Xiong, Yubin Xia, Jie Xiao, Xiaoyan Su, Yamei Wang, Xianrui Dou, Jinzhong Chen, Lifan Mei, Zhiqiang Xue, Yuanyuan Kong, Sijia Li, Hong Zhang, Ting Lin, Feng Wen, Xia Fu, Yiming Tao, Lei Fu, Zhuo Li, Renwei Huang, Zhiming Ye, Chaosheng He, Wei Shi, Xinling Liang, Guibao Ke, Shuangxin Liu. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure. Blood purification. 2022; 51(3):270-279. doi: 10.1159/000519643. [PMID: 34753147]
  • Douglas L Mann, Michael M Givertz, Justin M Vader, Randall C Starling, Palak Shah, Steven E McNulty, Kevin J Anstrom, Kenneth B Margulies, Michael S Kiernan, Claudius Mahr, Divya Gupta, Margaret M Redfield, Anuradha Lala, Gregory D Lewis, Adam D DeVore, Patrice Desvigne-Nickens, Adrian F Hernandez, Eugene Braunwald. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA cardiology. 2022 01; 7(1):17-25. doi: 10.1001/jamacardio.2021.4567. [PMID: 34730769]
  • Xuehui Liu, Hongjun Liu, Lijun Wang, Lei Zhang, Qiang Xu. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. PloS one. 2022; 17(1):e0263131. doi: 10.1371/journal.pone.0263131. [PMID: 35081164]
  • Jiabao Dong, Duo Huang, Ling Jing, Mengmeng Wu. Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway. Analytical cellular pathology (Amsterdam). 2022; 2022(?):4807028. doi: 10.1155/2022/4807028. [PMID: 36061150]
  • Jiafang Yao, Dan Liu. Clinical Effect of Qili Qiangxin Capsule Combined with Sacubitril-Valsartan in Patients with Chronic Heart Failure. Journal of healthcare engineering. 2022; 2022(?):8598806. doi: 10.1155/2022/8598806. [PMID: 35368935]
  • Bharathi Upadhya, Patrick M Kozak, Richard Brandon Stacey, Ramachandran S Vasan. Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Current hypertension reports. 2022 01; 24(1):1-20. doi: 10.1007/s11906-022-01166-9. [PMID: 35165832]
  • Haiping Du, Xiao Li, Weifang Zhao, Ning Jiang. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure. Journal of healthcare engineering. 2022; 2022(?):9494981. doi: 10.1155/2022/9494981. [PMID: 35222898]
  • Valeria R Martínez, Evelina G Ferrer, Patricia Am Williams. Candesartan, losartan and valsartan Zn(II) complexes interactions with bovine serum albumin. Future medicinal chemistry. 2022 01; 14(1):9-16. doi: 10.4155/fmc-2021-0216. [PMID: 34730021]
  • Zhaohua Cai, Liang Fang, Yangjing Jiang, Min Liang, Jian Wang, Yejiao Shen, Zi Wang, Feng Liang, Huanhuan Huo, Changqing Pan, Linghong Shen, Ben He. Angiotensin II Promotes White Adipose Tissue Browning and Lipolysis in Mice. Oxidative medicine and cellular longevity. 2022; 2022(?):6022601. doi: 10.1155/2022/6022601. [PMID: 35799891]
  • Roghayeh Pakdel, Mehran Vatanchian, Saeed Niazmand, Farimah Beheshti, Maryam Rahimi, Azita Aghaee, Mousa-Al-Reza Hadjzadeh. Comparing the effects of Portulaca oleracea seed hydro-alcoholic extract, valsartan, and vitamin E on hemodynamic changes, oxidative stress parameters and cardiac hypertrophy in thyrotoxic rats. Drug and chemical toxicology. 2022 Jan; 45(1):14-21. doi: 10.1080/01480545.2019.1651330. [PMID: 31414619]
  • Jui-Ning Yeh, Ya Yue, Yi-Ching Chu, Chi-Ruei Huang, Chih-Chao Yang, John Y Chiang, Hon-Kan Yip, Jun Guo. Entresto protected the cardiomyocytes and preserved heart function in cardiorenal syndrome rat fed with high-protein diet through regulating the oxidative stress and Mfn2-mediated mitochondrial functional integrity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021 Dec; 144(?):112244. doi: 10.1016/j.biopha.2021.112244. [PMID: 34601193]
  • Augustina Jankauskiene, Dorota Drozdz, Anna Wasilewska, Rejane de Paula-Bernardes, Robert Glazer, Michele Valentin, Monique Tan, YannTong Chiang, Kiran Bapatla. Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase. Current medical research and opinion. 2021 12; 37(12):2113-2122. doi: 10.1080/03007995.2021.1982681. [PMID: 34543161]
  • Longxue Cai, Wenfeng Li, Renqing Zeng, Zuohong Cao, Qicai Guo, Qi Huang, Xianfa Liu. Valsartan alleviates the blood-brain barrier dysfunction in db/db diabetic mice. Bioengineered. 2021 12; 12(1):9070-9080. doi: 10.1080/21655979.2021.1981799. [PMID: 34697992]
  • Bo Xiong, Dan Nie, Jun Qian, Yuanqing Yao, Gang Yang, Shunkang Rong, Que Zhu, Yun Du, Yonghong Jiang, Jing Huang. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC heart failure. 2021 12; 8(6):4852-4862. doi: 10.1002/ehf2.13677. [PMID: 34716749]
  • Tom Nolan. Tom Nolan's research reviews-26 November 2021. BMJ (Clinical research ed.). 2021 11; 375(?):n2938. doi: 10.1136/bmj.n2938. [PMID: 34836915]
  • Burkert Pieske, Rolf Wachter, Sanjiv J Shah, Abigail Baldridge, Peter Szeczoedy, Ghionul Ibram, Victor Shi, Ziqiang Zhao, Martin R Cowie. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021 11; 326(19):1919-1929. doi: 10.1001/jama.2021.18463. [PMID: 34783839]
  • Nitin Kumar, Yu Zuo, Srilakshmi Yalavarthi, Kristina L Hunker, Jason S Knight, Yogendra Kanthi, Andrea T Obi, Santhi K Ganesh. SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. Viruses. 2021 11; 13(11):. doi: 10.3390/v13112209. [PMID: 34835015]
  • Bahia Abbas Moussa, Hanaa M A Hashem, Marianne Alphonse Mahrouse, Sally Tarek Mahmoud. Synchronized determination of sacubitril and valsartan with some co-administered drugs in human plasma via UPLC-MS/MS method using solid-phase extraction. Biomedical chromatography : BMC. 2021 Nov; 35(11):e5203. doi: 10.1002/bmc.5203. [PMID: 34145610]
  • Marta Jiménez-Blanco Bravo, Alfonso Valle, Jara Gayán Ordás, Susana Del Prado Díaz, David Cordero Pereda, Herminio Morillas Climent, Ramón Bascompte Claret, Julia Seller Moya, José Luis Zamorano Gómez, Gonzalo Luis Alonso Salinas. Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry). Journal of cardiovascular pharmacology. 2021 11; 78(5):e662-e668. doi: 10.1097/fjc.0000000000001111. [PMID: 34321396]
  • Giuseppe Di Tano, Andrea Di Lenarda, Massimo Iacoviello, Fabrizio Oliva, Stefano Urbinati, Nadia Aspromonte, Manlio Cipriani, Pasquale Caldarola, Adriano Murrone, Michele Massimo Gulizia, Furio Colivicchi, Domenico Gabrielli. [ANMCO Position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure]. Giornale italiano di cardiologia (2006). 2021 Oct; 22(10):854-860. doi: 10.1714/3666.36517. [PMID: 34570120]
  • Wenwen Chen, Yanlin Liu, Yuanmin Li, Heqin Dang. Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study. ESC heart failure. 2021 10; 8(5):3783-3790. doi: 10.1002/ehf2.13491. [PMID: 34155812]
  • Roberto Pontremoli, Claudio Borghi, Pasquale Perrone Filardi. Renal protection in chronic heart failure: focus on sacubitril/valsartan. European heart journal. Cardiovascular pharmacotherapy. 2021 09; 7(5):445-452. doi: 10.1093/ehjcvp/pvab030. [PMID: 33822031]
  • Huang Kuang, Xin Huang, Zhifeng Zhou, Xuexin Cheng, Gaosi Xu. Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application. European journal of pharmacology. 2021 Sep; 907(?):174288. doi: 10.1016/j.ejphar.2021.174288. [PMID: 34216577]
  • Senthil Selvaraj, Brian L Claggett, Milton Packer, Faiez Zannad, Inder S Anand, Burkert Pieske, Ziqiang Zhao, Victor C Shi, Martin P Lefkowitz, John J V McMurray, Scott D Solomon. Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. 2021 09; 10(17):e022069. doi: 10.1161/jaha.121.022069. [PMID: 33998278]
  • Ying Li, Li Kang, Kai Rong, Yue Zhang, Ya Suo, Meng Yuan, Qiankun Bao, Shuai Shao, Gary Tse, Rong Li, Tong Liu, Guangping Li. Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome. Life sciences. 2021 Sep; 280(?):119692. doi: 10.1016/j.lfs.2021.119692. [PMID: 34102189]
  • Khalid Alhazzani, Moureq R Alotaibi, Faisal N Alotaibi, Khaldoon Aljerian, Homood M As Sobeai, Ali R Alhoshani, Ahmed Z Alanazi, Wael A Alanazi, Mohammed Alswayyed. Protective effect of valsartan against doxorubicin-induced cardiotoxicity: Histopathology and metabolomics in vivo study. Journal of biochemical and molecular toxicology. 2021 Sep; 35(9):e22842. doi: 10.1002/jbt.22842. [PMID: 34273911]
  • Marlies de Ligt, Matthijs K C Hesselink, Johanna Jorgensen, Johan W E Jocken, Ellen E Blaak, Gijs H Goossens. The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19. Obesity (Silver Spring, Md.). 2021 09; 29(9):1423-1426. doi: 10.1002/oby.23221. [PMID: 33955183]
  • Mona K Tawfik, Mohammed M Keshawy, Samy Makary. Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression. Molecular biology reports. 2021 Sep; 48(9):6457-6470. doi: 10.1007/s11033-021-06647-9. [PMID: 34431038]
  • Munaza Riaz, Steven M Smith, Eric A Dietrich, Carl J Pepine, Haesuk Park. Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. Pharmacotherapy. 2021 09; 41(9):710-721. doi: 10.1002/phar.2610. [PMID: 34170559]
  • Fangfang Sun, Deqi Jiang, Juanjuan Cai. Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis. BMC endocrine disorders. 2021 Aug; 21(1):178. doi: 10.1186/s12902-021-00844-0. [PMID: 34465338]
  • Pema Raj, Karen Sayfee, Mihir Parikh, Liping Yu, Jeffrey Wigle, Thomas Netticadan, Shelley Zieroth. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats. Molecules (Basel, Switzerland). 2021 Aug; 26(16):. doi: 10.3390/molecules26165006. [PMID: 34443591]
  • Cristina Prieto, Zoran Evtoski, María Pardo-Figuerez, Julia Hrakovsky, Jose M Lagaron. Nanostructured Valsartan Microparticles with Enhanced Bioavailability Produced by High-Throughput Electrohydrodynamic Room-Temperature Atomization. Molecular pharmaceutics. 2021 08; 18(8):2947-2958. doi: 10.1021/acs.molpharmaceut.1c00098. [PMID: 34181413]
  • Haiyan Wang, Xianghua Fu. Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coronary artery disease. 2021 Aug; 32(5):418-426. doi: 10.1097/mca.0000000000000932. [PMID: 32732515]
  • Fangyuan Chen, Gang Tian, Xiaojun Bai, Juanli Li, Zuyi Yuan. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction. Annals of palliative medicine. 2021 Aug; 10(8):8684-8691. doi: 10.21037/apm-21-157. [PMID: 34488357]
  • Dominick Mkombozi Raphael, Zhiyu Liu, Zhi Jin, Xinyue Cui, Dongjian Han, Weiwei He, Jiahong Shangguan, Deliang Shen. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease. Current medical research and opinion. 2021 07; 37(7):1071-1078. doi: 10.1080/03007995.2021.1908243. [PMID: 33764230]
  • Huayu Yang, Haiping Chen, Fenghua Liu, Qing Ma. Up-regulation of matrix metalloproteinases-9 in the kidneys of diabetic rats and the association with neutrophil gelatinase-associated lipocalin. BMC nephrology. 2021 06; 22(1):211. doi: 10.1186/s12882-021-02396-w. [PMID: 34082748]
  • Komuraiah Myakala, Bryce A Jones, Xiaoxin X Wang, Moshe Levi. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment. American journal of physiology. Renal physiology. 2021 06; 320(6):F1133-F1151. doi: 10.1152/ajprenal.00614.2020. [PMID: 33870733]
  • Guanghao Niu, Mi Zhou, Feng Wang, Jingxing Yang, Jie Huang, Zengyan Zhu. Marein ameliorates Ang II/hypoxia-induced abnormal glucolipid metabolism by modulating the HIF-1α/PPARα/γ pathway in H9c2 cells. Drug development research. 2021 06; 82(4):523-532. doi: 10.1002/ddr.21770. [PMID: 33314222]
  • Sarah Petch, Emily O'Connor, Ailbhe McGrath, Sean Daly. Valsartan exposure in pregnancy with resultant anhydramnios and chronic kidney disease in a late preterm infant. BMJ case reports. 2021 May; 14(5):. doi: 10.1136/bcr-2020-240810. [PMID: 34011666]
  • Marika Turek, Ewa Różycka-Sokołowska, Marek Koprowski, Bernard Marciniak, Piotr Bałczewski. Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential. Molecular pharmaceutics. 2021 05; 18(5):1970-1984. doi: 10.1021/acs.molpharmaceut.0c01096. [PMID: 33792313]
  • Yasuyuki Kitaura, Daichi Shindo, Tatsuya Ogawa, Ayato Sato, Yoshiharu Shimomura. Antihypertensive drug valsartan as a novel BDK inhibitor. Pharmacological research. 2021 05; 167(?):105518. doi: 10.1016/j.phrs.2021.105518. [PMID: 33636353]
  • João Pedro Ferreira, Brian L Claggett, Jiankang Liu, Akshay S Desai, Marc A Pfeffer, Inder S Anand, Dirk J van Veldhuisen, Lars Kober, John G F Cleland, Jean L Rouleau, Milton Packer, Michael R Zile, Victor C Shi, Martin P Lefkowitz, Sanjiv J Shah, Orly Vardeny, Faiez Zannad, Scott D Solomon, John J V McMurray. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. European journal of heart failure. 2021 05; 23(5):776-784. doi: 10.1002/ejhf.2134. [PMID: 33609066]
  • Xiaoping Chen, Linzi Long, Ying Cheng, Jianfeng Chu, Zhiqing Shen, Liya Liu, Jiapeng Li, Qiurong Xie, Huixin Liu, Meizhu Wu, Youqin Chen, Jun Peng, Aling Shen. Qingda granule attenuates cardiac fibrosis via suppression of the TGF-β1/Smad2/3 signaling pathway in vitro and in vivo. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021 May; 137(?):111318. doi: 10.1016/j.biopha.2021.111318. [PMID: 33556875]
  • Dan Nie, Bo Xiong, Jun Qian, Shunkang Rong, Yuanqing Yao, Jing Huang. The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis. Heart, lung & circulation. 2021 May; 30(5):683-691. doi: 10.1016/j.hlc.2020.10.012. [PMID: 33199181]
  • Mehrnoush Taherzadeh Ghahfarrokhi, Shakiba Zeinali, Habib Bagheri. Preparation of amine-modified lignin and its applicability toward online micro-solid phase extraction of valsartan and losartan in urine samples. Journal of chromatography. A. 2021 Apr; 1643(?):462081. doi: 10.1016/j.chroma.2021.462081. [PMID: 33780883]
  • Zhihua Pang, Chang Pan, Zhuhua Yao, Ying Ren, Liuyang Tian, Jian Cui, Ximei Liu, Lijun Zhang, Ying Chen. A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial. Medicine. 2021 Apr; 100(16):e25621. doi: 10.1097/md.0000000000025621. [PMID: 33879733]
  • Marie-Camille Chaumais, Mohamed Reda Amar Djessas, Raphaël Thuillet, Amélie Cumont, Ly Tu, Guillaume Hebert, Pauline Gaignard, Alice Huertas, Laurent Savale, Marc Humbert, Christophe Guignabert. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovascular research. 2021 04; 117(5):1391-1401. doi: 10.1093/cvr/cvaa200. [PMID: 32653925]
  • Xiaojing Yang, Wu Luo, Li Li, Xiang Hu, Mingjiang Xu, Yi Wang, Jianpeng Feng, Jianchang Qian, Xinfu Guan, Yunjie Zhao, Guang Liang. CDK9 inhibition improves diabetic nephropathy by reducing inflammation in the kidneys. Toxicology and applied pharmacology. 2021 04; 416(?):115465. doi: 10.1016/j.taap.2021.115465. [PMID: 33631230]
  • Ravi B Patel, Jozine M Ter Maaten, João Pedro Ferreira, Finnian R McCausland, Sanjiv J Shah, Patrick Rossignol, Scott D Solomon, Muthiah Vaduganathan, Milton Packer, Aliza Thompson, Norman Stockbridge, Faiez Zannad. Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation. 2021 03; 143(9):949-958. doi: 10.1161/circulationaha.120.049514. [PMID: 33406882]
  • Rachel Ryu, Huyentran Tran, Khaled Bahjri. Association of Sacubitril/Valsartan with Metabolic Parameters in Patients with Reduced Ejection Fraction Heart Failure at a Multidisciplinary Clinic. Metabolic syndrome and related disorders. 2021 03; 19(2):115-118. doi: 10.1089/met.2020.0100. [PMID: 33155868]
  • Hui-Ling Hsieh, Chun-You Chen, Cheng-Hsien Chen, Shih-Chang Hsu, Wen-Cheng Huang, Yuh-Mou Sue, Feng-Yen Lin, Chun-Ming Shih, Yue-Cune Chang, Po-Hsun Huang, Chung-Te Liu. Renal protective effect of sacubitril/valsartan in patients with heart failure. Scientific reports. 2021 02; 11(1):4593. doi: 10.1038/s41598-021-84118-8. [PMID: 33633282]
  • Giuseppe Vergaro, Paolo Sciarrone, Concetta Prontera, Silvia Masotti, Veronica Musetti, Alessandro Valleggi, Alberto Giannoni, Michele Senni, Michele Emdin, Claudio Passino. Renin profiling predicts neurohormonal response to sacubitril/valsartan. ESC heart failure. 2021 02; 8(1):719-724. doi: 10.1002/ehf2.13085. [PMID: 33216460]
  • Antonio Vitiello, Raffaele La Porta, Francesco Ferrara. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Medical hypotheses. 2021 Feb; 147(?):110486. doi: 10.1016/j.mehy.2021.110486. [PMID: 33460992]